Fast-acting insulin aspart regulatory update

Novo Nordisk resubmitted an NDA to FDA for fast-acting insulin aspart to treat Type I and II diabetes. Novo expects to receive feedback from the agency in 4Q17. Last year, FDA issued a complete respon...